Oxaprozin
From Self-sufficiency
| File:Oxaprozin.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid | |
| Clinical data | |
| Pregnancy category |
|
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Protein binding | 99% |
| Metabolism | Liver—65% oxidation and 35% glucuronic acid conjugation. 5% are active phenolic metabolites. |
| Biological half-life | 54.9 hours |
| Identifiers | |
| CAS Number | 21256-18-8 |
| ATC code | M01AE12 (WHO) |
| PubChem | CID 4614 |
| DrugBank | APRD00030 |
| Chemical data | |
| Formula | C18H15NO3 |
| Molar mass | 293.317 g/mol[[Script error: No such module "String".]] |
| (verify) | |
Oxaprozin, also known as Oxaprozinum, (sold under the names: Daypro or Duraprox) is a non-steroidal anti-inflammatory drug (NSAID),[1] used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. It is available in 600 mg tablets. Normal adult dosage is 1200 mg daily, not to exceed 1800 mg per day. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 45px | This drug article relating to the musculoskeletal system is a stub. You can help ssf by expanding it. |
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Non-steroidal anti-inflammatory drugs
- Oxazoles
- 2Fix
- Musculoskeletal system drug stubs
